Menu
← Oncology Approval Tracker
FDA DECISION ·
Tecentriq / Tecentriq Hybreza
atezolizumab or atezolizumab and hyaluronidase-tqjs · Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adjuvant use with fluoropyrimidine and oxaliplatin in stage III dMMR colon cancer. IV Tecentriq applies from age 2. Subcutaneous Tecentriq Hybreza applies from age 12 and at least 40 kg.
SUPPORTING DATA
Evidence behind the decision
- Study
- ATOMIC randomized 712 patients after resection, including one pediatric participant, to mFOLFOX6 with or without atezolizumab.
- Key result
- The hazard ratio for disease recurrence or death was 0.50 (95% CI, 0.35–0.73). Median disease-free survival was unreached in both groups.
- Safety to report
- FDA labeling flags immune-mediated and infusion-related reactions, among other risks.
- Evidence limits
- This result is for disease-free survival. Report the small pediatric sample separately from the age ranges in the label.
LAMPGEN ANALYSIS
Why it matters
Mismatch repair status now guides an adjuvant immunotherapy decision in stage III colon cancer. The ATOMIC study measured disease-free survival after surgery.
What research teams should watch
Confirm MMR status from the surgical pathology record and match age and weight to the chosen formulation. Track recurrence assessments and immune-related safety across the chemotherapy and monotherapy phases.
PRIMARY RECORDS